Publications: Stephen Ezell

Recent policies permitting CMS price setting are hamstringing the U.S. biopharmaceutical industry, as they reduce incentives for pharmaceutical companies to invest in future drug R&D to create life-improving and life-saving medicines.

The Inflation Reduction Act (IRA) undermines innovation in small-molecule drugs by subjecting them to price controls after 9 years, whereas large-molecule drugs (biologics) are allowed 13 years of market pricing. Congress should pass the bipartisan EPIC Act to remedy this issue.

The 1984 Hatch-Waxman Act revolutionized the U.S. pharmaceutical industry, successfully balancing the interests of pharmaceutical innovation and affordability by creating legal pathways for accelerated generic drug competition while extending patent protections and introducing data exclusivities that preserved incentives for novel pharmaceutical innovation.

Trump’s proposed 100 percent tariffs on Taiwanese chips would hike prices, hurt U.S. tech, help China, and alienate a key ally—without bringing jobs home.

The Biden administration's proposed export controls would impose sweeping restrictions on chip exports, risking U.S. competitiveness while failing to effectively address national security concerns.

Reviving U.S. semiconductor manufacturing requires targeted solutions—not broad tariffs that raise costs and hinder global competitiveness.

Again and again, America has pioneered new technologies and then frittered away its leadership—in sectors ranging from semiconductors and solar panels, to televisions and medical devices. We can’t afford to squander another lead in multi-cancer early detection (MCED) because of regulatory roadblocks.

Many of the world’s biggest challenges are health challenges. The good news is that, more than ever, people are meeting these challenges with innovative solutions.

For policymakers to bolster the global competitiveness of their nations and regions, they first must know where they stand. This report benchmarks the 87 regions of India and the United States using 13 commonly available indicators of strength in the knowledge economy, globalization, and innovation capacity.

The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.